Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.5138 -0.0162 (-3.06%)
Streaming Delayed Price Updated: 12:58 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 515,923
Open 0.5200
Bid (Size) 0.5117 (600)
Ask (Size) 0.5150 (500)
Prev. Close 0.5300
Today's Range 0.5028 - 0.5395
52wk Range 0.5100 - 5.140
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding The Upcoming Lead Plaintiff Deadline for the Filed Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-24.3%
-24.3%
1 Month
-28.6%
-28.6%
3 Month
-87.7%
-87.7%
6 Month
-82.7%
-82.7%
1 Year
-82.0%
-82.0%

More News

Read More
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
From Vistagen
Via Business Wire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Class Action Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
VISTAGEN CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
VTGN Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
News headline image
VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?
Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?
Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?
The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market
What is the current price of Vistagen Therapeutics, Inc. - Common Stock?
The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.5138
When was Vistagen Therapeutics, Inc. - Common Stock last traded?
The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 02/05/26 12:58 PM ET
What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?
The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 4.81M
How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?
Vistagen Therapeutics, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.